Acurx Pharmaceuticals Aktie [WKN DE: A3CSCG / ISIN: US00510M1045]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Acurx Pharmaceuticals Inc Registered Shs

29.01.24		Acurx Pharma Reports Positive Data From Phase 2b Study Of Ibezapolstat In CDI (RTTNews)
17.01.24		Why Is Antibiotic Player Acurx Pharmaceuticals Stock Trading Lower Today? (Benzinga)
17.01.24		Acurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Trial (RTTNews)
11.12.23		Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure (PR Newswire)
14.11.23		Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update (PR Newswire)
02.11.23		Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection (PR Newswire)
25.10.23		Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
19.10.23		Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences (PR Newswire)
02.10.23		Acurx Pharma Discontinues Phase 2b Trial For Ibezapolstat To Treat C. Difficile Infection (RTTNews)
02.10.23		Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection (PR Newswire)
12.09.23		Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress (PR Newswire)
22.08.23		Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 (PR Newswire)
14.08.23		Acurx Pharma's Phase 2b Study Of Ibezapolstat In C. Difficile Infection On Track (RTTNews)
14.08.23		Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update (PR Newswire)
24.07.23		Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
20.06.23		Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023 (PR Newswire)
15.06.23		Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET (PR Newswire)
16.05.23		Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering (PR Newswire)
12.05.23		Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update (PR Newswire)
05.05.23		Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
19.04.23		Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference (PR Newswire)
11.04.23		FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference (PR Newswire)
16.03.23		Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (PR Newswire)
06.03.23		Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update (PR Newswire)
16.01.23		Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023 (PR Newswire)
14.11.22		Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update (PR Newswire)
01.11.22		Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update (PR Newswire)
26.10.22		Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022 (PR Newswire)
17.10.22		Acurx Announces Scientific Oral and Poster Presentations at IDWeek (PR Newswire)
15.08.22		Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update (PR Newswire)
04.08.22		Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update (PR Newswire)
02.08.22		Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America (PR Newswire)
25.07.22		Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering (PR Newswire)
11.05.22		Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update (PR Newswire)
29.04.22		Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update (PR Newswire)
17.03.22		Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update (PR Newswire)
16.03.22		Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT (PR Newswire)
07.03.22		Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update (PR Newswire)
07.02.22		Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases (PR Newswire)
06.12.21		Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) (PR Newswire)
13.11.21		Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update (PR Newswire)
08.11.21		Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference (PR Newswire)
01.11.21		Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference (PR Newswire)
27.10.21		Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update (PR Newswire)
04.10.21		Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek (PR Newswire)
30.09.21		Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 (PR Newswire)
29.09.21		Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021 (PR Newswire)
27.09.21		Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference (PR Newswire)
02.09.21		Acurx Pharmaceuticals to Join the Russell Microcap Index® (PR Newswire)
31.08.21		Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 18:10
Kaufwert:	EUR
	Hinzufügen Speichern